Event date
  • Biopsychosocial
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 APA
  • 1.00 ASWB-ACE
  • 1.00 Contact Hours/ Participation
In the last two decades, psychedelics have re-emerged as promising novel agents for treatment of a broad range of mental health conditions including depression, PTSD, substance use disorders, end-of-life anxieties, eating disorders, and more. Our understanding of their putative mechanisms of action has significantly evolved as well. Several Phase II and III clinical trials of psychedelic-assisted therapy (PAT) using psilocybin and MDMA are either complete or nearing completion, with some of these therapies projected to receive FDA approval within the next couple of years.
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 APA
  • 1.50 ASWB-ACE
  • 1.50 Contact Hours/ Participation
In 2021, US Surgeon General Dr. Vivek Murthy described experiences of loneliness as “a dark thread through our nation’s most pressing public health challenges” (Murthy, 2021, Public Health Reports, 136[6]). Rates of loneliness across the globe have increased across age and demographic groups steadily over the past two decades, despite concomitant changes in communication technology and virtual interconnectedness.